Genomic heart disease drug developer Verve Therapeutics secured funding in a round led by GV, which also led its series A last year.

GV, a corporate venturing subsidiary of internet and technology group Alphabet, has led a $63m series A2 round for Verve Therapeutics, a US-based developer of genomic heart disease drugs. F-Prime Capital, a subsidiary of investment and financial services firm Fidelity, also took part in the round, as did Arch Venture Partners, Biomatics Capital, Wellington Management…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.